

VasDeBlock medical ApS Announces Issuance of a Patent in the USA

2022.06.23.

Copenhagen, Denmark. VasDeBlock medical ApS, a medico tech company focusing on the development of a device and methods for long-acting, reversible contraception for men, announces approval of the company's key patent in USA.

The issued patent "Occlusion device for reversible occlusion of a biological tube", U.S. Patent no. 11,337,849 (the '849 patent) covers the company's invention of methods, systems and devices to prevent pregnancy on a long-term basis.

The US patent is the fourth grant in the patent family where related patents were previously granted in Denmark, Australia and Japan.

"We are pleased to have secured the patent for our non-hormonal, non-surgical, easily reversible contraceptive allowing men to participate in the family planning" said Mette Mikkelsen, CEO of VasDeBlock. "This latest patent approval is an important step in our development of long-acting, reversible male contraception".

The VasDeBlock patent portfolio encompasses a device and methods for administering it – without need for surgery – to effectively block spermatozoa from reaching the ejaculate and by similar simple means removing device when protection is no longer needed.

It's a long sought for alternative to traditional male sterilization (vasectomy) and controversial hormonal contraception and has raised great international interest. It will not prevent STDs.

The comprehensive patent coverage secures exclusivity to develop the products and methods. The company's strategy is to actively seek new patentable innovations from its device and method development programs.

